BioMedNewsBreaks

TuesdayDec 08, 2020 11:15 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant…

Continue Reading

MondayDec 07, 2020 10:10 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological crop protection for high value crops, today announced an upcoming live webcast for its investment community. According to the update, MustGrow is poised to capitalize in 2021 and beyond in a rapidly growing market as regulatory framework moves to favor organic biopesticides and bioherbicides. The webcast is scheduled to take place at 11:00 a.m. ET on Wednesday, Dec. 9, 2020. Interested parties may visit https://ibn.fm/9Jz3E to register for the event and are asked to join five minutes before the beginning of the webcast. To view…

Continue Reading

FridayDec 04, 2020 11:11 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) to Showcase NeuroCap(TM) at AES2020

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that it will participate in AES2020 – the all-new virtual event for epilepsy professionals in academia, clinical practice, industry and advocacy. Slated to take place on Dec. 4–8, 2020, the American Epilepsy Society's Annual Meeting is the largest meeting and exhibition in the world to share common scientific and clinical interests in epilepsy and clinical neurophysiology. “Brain Scientific has successfully taken part in AES conferences before, and this year we will have a virtual booth at this important event. We will be showing the new version of…

Continue Reading

ThursdayDec 03, 2020 3:25 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life Sciences CEO Dr. James Woody is scheduled to present at 1:40 p.m. EST on Tuesday, Dec. 15. Interested parties should visit https://ibn.fm/KHrgf to register for the event. The 2020 LD Micro Main Event will feature a new and unique format with companies presenting for 10…

Continue Reading

ThursdayDec 03, 2020 12:49 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Benzinga Global Small Cap Conference taking place virtually on Dec. 8-9, 2020. Genprex’s president and CEO, Rodney Varner, will deliver a company overview that includes recent progress the company has made on its upcoming Acclaim-1 clinical trial. Varner’s presentation is scheduled to begin at 2:30 p.m. EST on Tuesday, Dec. 8. Investors and other interested parties should visit https://ibn.fm/VdFrh to register for the event. To view the full press release, visit https://ibn.fm/EPK3b About Genprex Inc. Genprex is a…

Continue Reading

WednesdayDec 02, 2020 11:16 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Files Patent Application for Flexible EEG Cap

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” “The new EEG product for which Brain Scientific is seeking a patent approval is a flexible head cap for conducting electroencephalography,” said BRSF Marketing Director Irina Nazarova. “The cap carries multiple dry electrodes that are placed at various positions corresponding to various channels for bio-signal collection.” To view the full press release, visit https://ibn.fm/jarkd About Brain Scientific Brain Scientific is a commercial-stage health care company…

Continue Reading

WednesdayDec 02, 2020 10:52 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was held but no business was conducted because a full quorum was not in attendance. The meeting has been rescheduled for Dec. 30, 2020 at 3 p.m. CST. Arrangements have been made for stockholders can attend via a live audio webcast, allowing more opportunity for stockholders to vote on proposals outlined in the definitive proxy statement filed by Predictive Oncology with the Securities and Exchange Commission…

Continue Reading

TuesdayDec 01, 2020 1:19 pm

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Test Results for Control of Threat to $25 Billion Banana Industry

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has announced initial test results of its mustard-derived organic biopesticide formulation designed to control Fusarium wilt TR4, a destructive pathogen threatening the global banana industry, which is valued at $25 billion. Completed via third-party independent laboratory CyberAgrot SAS in Colombia, the testing reported 100% control Fusarium wilt TR4, known as Panama disease. The disease led to the declaration of a national state of emergency in Colombia in 2019. Based on what the company has been able to determine, complete control of this disease has never been achieved. The company is now planning more advanced…

Continue Reading

TuesdayDec 01, 2020 10:30 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. “Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner,…

Continue Reading

TuesdayDec 01, 2020 9:00 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine

VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen's PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential for the rapid-onset treatment of anxiety and depression disorders, respectively. VistaGen is a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Throughout…

Continue Reading